Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Tracking Patient Manifestations of Behçet’s Syndrome around the World

Yusuf Yazici, MD  |  Issue: July 2010  |  July 1, 2010

BS is most commonly seen in Mediterranean countries and the Far East along the ancient Silk Road, suggesting that the putative agent(s)—including several genetic factors such as human leukocyte antigen–B51 (HLA-B51)—may have spread along this path. In field surveys carried out in Turkey, the prevalence of BS was found to be between 20 and 421 cases per 100,000 adults. The disease is reported to be less frequent in the rest of the world, with an estimated prevalence ranging from 0.64 per 100,000 persons in the U.K. to 6.4 per 100,000 in Spain and 5.2 per 100,000 in the U.S. However, a more specific analysis of Turkish people living in Germany has demonstrated a distinctly high prevalence rate of 77 cases per 100,000 individuals. These findings may indicate the greater significance of genetic factors over environmental factors in the etiology.

Some manifestations of BS show regional differences. GI involvement is more frequently observed in patients from the Far East than among those from Turkey. Although a positive pathergy test is common among patients in countries and regions ranging from Turkey and the Mediterranean to Japan, it is less commonly seen in Northern European countries and the U.S. Finally, the HLA-B51 association is most pronounced among patients from the Middle and Far East.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The usual onset of the syndrome is in the third decade of life; onset of BS is uncommon among the older population (older than 50 years) and in children. Both sexes are equally affected; however, the syndrome runs a more severe disease course in men and in the young.

Figure 2: Positive pathergy reaction in a patient with BS.
Figure 2: Positive pathergy reaction in a patient with BS.

Mucocutaneous features are the most common presenting symptoms of the disease, although ocular, vascular, and neurological symptoms are the most serious symptoms. Almost all patients have recurrent oral ulceration. These ulcers are frequently the first observed symptom and may precede the other manifestations of BS by many years. Although aphthae are usually multiple and occur frequently in BS, they are indistinguishable from those of recurrent oral ulcers due to other causes. Genital ulcers usually occur on the scrotum in males, but they are infrequent on the shaft or on the glans penis; urethritis or dysuria is not a part of BS. In females, both major and minor labia are affected. The ulcers usually heal in two to four weeks; a large ulcer will frequently leave a scar, while a small ulcer and those on the minor labia heal without scarring. Both types of ulcers can be painful, even though painful oral ulcers are seen more frequently than genital ones.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 4 5 6 7 | Single Page
Share: 

Filed under:Clinical Criteria/GuidelinesConditions Tagged with:Behçet’s diseaseDiagnostic CriteriaPathogenesisTreatment

Related Articles

    Case Report: An Unusual Presentation of Neuro-Behçet’s Disease

    April 15, 2022

    A 44-year-old woman presented to the emergency department with bifrontal headaches that had started approximately one month earlier. She was diagnosed with migraines and discharged home. Three days later, the patient returned to the emergency department upon recurrence of her headaches, and this time she also reported abnormal leg movements. A computerized tomography (CT) scan…

    Case Report: A Behçet’s Patient Develops Cerebral Venous Sinus Thrombi

    December 17, 2018

    A 39-year-old woman presented at the emergency department with three weeks of progressive, constant and pulsatile right-sided headache. She said her headache was worse in the morning and when she would bend forward. She reported associated nausea and vomiting. On initial assessment, she did not have any focal neurological deficits. Her medical history was significant for…

    Case Report: Which Vasculitis Is It?

    June 15, 2020

    A 13-year-old, adopted girl of unknown ancestry with social anxiety, selective mutism and Takayasu arteritis presented for evaluation of severe, painful, gingival hyperplasia, which limited her oral intake and resulted in weight loss. The young patient was diagnosed with Takayasu arteritis at age 8, when she presented with a persistently elevated erythrocyte sedimentation rate (ESR),…

    Ustekinumab for Behçet’s Disease? The Study Results Are In

    June 15, 2020

    In a multicenter, prospective, open-label study, ustekinumab therapy was effective in treating oral ulcers resistant to colchicine in patients with Behçet’s disease, according to study author David Saadoun, MD, PhD, Department of Internal Medicine and Clinical Immunology, Sorbonne University, Paris, and fellow researchers.1 Researchers focused on the topic because oral ulcers are often disabling, have…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences